Current SATVI news
Researchers the South African Tuberculosis Vaccine Initiative (SATVI), the Center for Global Infectious Disease Research(USA) and a large consortium of collaborators have developed a validated a new, simple blood-based test that has the potential to serve multiple functions in the fight against TB.
Scientists from UCT and Stanford Medicine University have developed a new method to compare and find commonalities within millions of T cell receptors (TCR), the receptors used by T cells to recognise pathogens.
The 2019 SATVI Annual Report is now available online.
Professor Val Mizrahi and Tom Scriba have co-authored a journal article titled "Renewing the Fight Against TB With an Old Vaccine" appearing in the Cell journal.
SATVI researchers Professor Tom Scriba, Associate Professor Elisa Nemes, Cheleka Mpande and Tim Reid have co-authored a journal article titled "Immune Phenotype and Functionality of Mtb-Specific T-Cells in HIV/TB Co-Infected Patients on Antiretroviral Treatment" appearing in the Pathogens journal.
Due to the lockdown announced by the South African President, we want to bring the following information to the attention of all participants in SATVI studies.
Professors Mark Hatherill, Tom Scriba, Doctors Simon Mendelsohn & Mbandi have authored an article titled: "Blood transcriptional signatures for tuberculosis testing" appearing in the Lancet Respiratory Medicine.
A paper which UCT’s Professors Mark Hatherill, Robert Wilkinson, Tom Scriba, Drs. Michèle Tameris and Friedrich Thienemann played a key role, has been selected as the best paper of the year for 2019.
Professor Mark Hatherill has co-authored a journal article titled: "Clinical Development of New TB Vaccines: Recent Advances and Next Steps" appearing in the Frontiers in Microbiology journal.
SATVI researcher Professor Tom Scriba and Stanley Kimbung Mbandi have co-authored an article titled "Immune correlates of tuberculosis disease and risk translate across species" appearing in the Science Translational Medicine journal.
Professor Tom Scriba and Dr Simon Mendelsohn have published a journal article titled: "Making headway towards biosignatures for incipient tuberculosis" appearing in the Lancet Respiratory Medicine.
The Prevention of Recurrence (POR) Consortium has been awarded a substantial grant from the European & Developing Countries Clinical Trial Partnership (EDCTP) which will support a clinical trial in South Africa and Tanzania of a new and promising tuberculosis (TB) vaccine candidate H56:IC31, developed by the Statens Serum Institute (SSI).